Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Sysco Corp.
SYYConsumer StaplesGenerated Sep 5, 2026, 01:36 PM UTC
SYY (Sysco Corp.) analytical snapshot. Revenue grew +3.9% YoY to $84.55B. 5-year revenue CAGR +4.3%; 10y CAGR +4.8%. Net margin at 2.08% (contracting ▼). Market cap $38.35B at $80.05 per share. Trailing P/E 21.87, P/S 0.45, P/B 14.39. EV/Operating income ≈ 15.24 (EV $47.15B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -15 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Aug 21, 2026. Latest quarterly report (10-Q) filed Apr 29, 2026. 18 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Aug 21, 2026.
- Latest quarterly report (10-Q) filed Apr 29, 2026.
- 18 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Sysco Corp.; broad institutional reporting.
- Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 20 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Aug 9, 2002 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 8, 2001 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 15, 2003 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Nov 2, 2001 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 11, 2004 |
| Date | Form | Description |
|---|---|---|
| Sep 4, 2026 | 8-K | FORM 8-K |
| Aug 20, 2026 | 8-K | 8-K |
| Aug 12, 2026 | 8-K | FORM 8-K |
| Aug 4, 2026 | 8-K | 8-K |
| Jul 2, 2026 | 8-K | FORM 8-K |
| May 18, 2026 | 8-K | FORM 8-K |
| Apr 28, 2026 | 8-K | 8-K |
| Apr 20, 2026 | 8-K | 8-K |
SEC Filing Deep-Analysis
3 risk signal(s), 1 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 3 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Going concern doubt in latest filing: The term "going concern" "substantial doubt" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
- NEW: Substantial doubt about ability to continue in latest filing: The term "substantial doubt" "ability to continue" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
- Restatement of financial statements: The term "restatement of" "previously issued" appears in 2 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
- Operating cash flow exceeds net income: OCF is 1.50x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 3 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 18 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 6 disclosure(s) dropped from prior year — reduced reporting granularity.
- 3 new risk-language term(s) detected in filing text: Going concern doubt, Substantial doubt about ability to continue, Impairment charge.
- Ongoing high-severity risk language: Restatement of financial statements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $81.37B | $84.55B | $3.18B | +3.9% |
| Gross profit | $14.97B | $15.64B | $670.0M | +4.5% |
| Operating income | $3.09B | $3.10B | $7.0M | +0.2% |
| Net income | $1.83B | $1.76B | $-71.0M | -3.9% |
| Operating cash flow | $2.51B | $2.64B | $128.0M | +5.1% |
| Capex | $906.0M | $700.0M | $-206.0M | -22.7% |
| Total assets | $26.77B | $28.40B | $1.62B | +6.1% |
| Long-term debt | $12.90B | $10.59B | $-2.31B | -17.9% |
| Cash & equivalents | $1.07B | $1.79B | $715.0M | +66.8% |
| Stockholders equity | $1.83B | $2.67B | $836.0M | +45.7% |
| Inventory | $1.77B | $2.07B | $302.2M | +17.1% |
| Interest expense | $113.4M | $128.5M | $15.1M | +13.3% |
| Type | Concepts |
|---|---|
| Added | AssetsFairValueDisclosure, CashAndCashEquivalentsFairValueDisclosure, EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance, EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther, EffectiveIncomeTaxRateReconciliationTaxContingencies, EffectiveIncomeTaxRateReconciliationTaxCredits, FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear, GoodwillWrittenOffRelatedToSaleOfBusinessUnit, IncomeTaxPaidForeignAfterRefundReceived, IncomeTaxPaidStateAndLocalAfterRefundReceived |
| Removed | CapitalizedComputerSoftwareGross, DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1, GainLossRelatedToLitigationSettlement, MinorityInterestDecreaseFromRedemptions, OciBeforeReclassificationsNetOfTaxAttributableToParent, OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 3 | 0 | NEW |
| Substantial doubt about ability to continue | high | 3 | 0 | NEW |
| Restatement of financial statements | high | 2 | 1 | Ongoing |
| Impairment charge | medium | 5 | 0 | NEW |
| Restructuring | medium | 5 | 9 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 2 | Ongoing |
| Related party transactions | low | 5 | 1 | Ongoing |
Fundamentals
Revenue grew +3.9% YoY to $84.55B. 5-year revenue CAGR +4.3%; 10y CAGR +4.8%. Net margin at 2.08% (contracting ▼).
- Revenue grew +3.9% YoY to $84.55B.
- 5-year revenue CAGR +4.3%; 10y CAGR +4.8%.
- Net margin at 2.08% (contracting ▼).
- Return on equity 65.90%, ROA 6.19%, ROIC 116.09%.
- Gross margin 18.50%, operating margin 3.66%.
- Free cash flow margin 2.29% ($1.94B).
- Net income down ▼ +3.9% YoY.
- Debt/equity 3.97, current ratio 1.28, net debt $8.80B.
- Asset turnover 2.98 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2025 | $81.37B | +3.2% | 18.40 | 3.80 | 2.25 | $1.60B | 99.89 |
| 2026 | $84.55B | +3.9% | 18.50 | 3.66 | 2.08 | $1.94B | 65.90 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Sep 28, 2024 | $20.48B | — | — | 2.39% |
| Dec 28, 2024 | $20.15B | — | -1.6% | 2.01% |
| Mar 29, 2025 | $19.60B | — | -2.7% | 2.05% |
| Sep 27, 2025 | $21.15B | — | +7.9% | 2.25% |
| Dec 27, 2025 | $20.76B | — | -1.8% | 1.87% |
| Mar 28, 2026 | $20.52B | — | -1.2% | 1.66% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $38.35B at $80.05 per share. Trailing P/E 21.87, P/S 0.45, P/B 14.39. EV/Operating income ≈ 15.24 (EV $47.15B).
- Market cap $38.35B at $80.05 per share.
Price & Technicals
Price $80.05 — uptrend (above 200-DMA); 1-month momentum negative. RSI(14) 39.23.
- Price $80.05 — uptrend (above 200-DMA); 1-month momentum negative.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.77%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Elevated. Leverage debt/equity 3.97 (high). Liquidity current ratio 1.28 (adequate).
- Composite risk: Elevated.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite -15
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Sysco Corp. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewMarket regime: Risk-on · Supportive..
Peer comparison
Defensive groupHow SYY stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 21 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Gilead Sciences GILD | 10 | Neutral |
| Regeneron Pharmaceuticals REGN | 10 | Neutral |
| Johnson & Johnson JNJ | 10 | Neutral |
| Eli Lilly & Co. LLY | 9 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| HCA Healthcare HCA | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Coca-Cola Co. KO | 3 | Neutral |
| Intuitive Surgical Inc. ISRG | 2 | Neutral |
| Merck & Co. MRK | 2 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Cigna Group CI | 0 | Neutral |
| Vertex Pharmaceuticals VRTX | 0 | Neutral |
| AbbVie Inc. ABBV | -2 | Neutral |
| Colgate-Palmolive CL | -4 | Neutral |
| CVS Health Corp. CVS | -6 | Neutral |
| Kroger Co. KR | -8 | Neutral |
| Amgen Inc. AMGN | -8 | Neutral |
| Procter & Gamble PG | -10 | Neutral |
| Pfizer Inc. PFE | -11 | Neutral |
| Mondelez International MDLZ | -13 | Neutral |
| Sysco Corp. SYY● you | -15 | Neutral |
| Moderna Inc. MRNA | -19 | Neutral |
| Walmart Inc. WMT | -20 | Neutral |
| Costco Wholesale COST | -20 | Neutral |
| UnitedHealth Group UNH | -21 | Neutral |
| Hershey Co. HSY | -22 | Neutral |
| PepsiCo Inc. PEP | -22 | Neutral |
| Kimberly-Clark Corp. KMB | -24 | Neutral |